Bardoxolone is an investigational oral nuclear factor erythroid-derived 2-related factor 2 (Nrf2) activator proposed to slow the progression of kidney disease in patients aged ≥ 12 years with chronic kidney disease caused by Alport Syndrome.

If you have a Hayes login, click here to view the full report on the Knowledge Center.